張文宏

發布時間：2021-06-28瀏覽次數：15530

教師基本信息

姓名：張文宏

職稱：教授

電子郵箱：zhangwenhong@fudan.edu.cn

辦公地點：生科院C507

個人簡介

張文宏，男，教授，博士生導師，万博体育分 PI。教育部長江學者特聘教授，國家衛健委突出貢獻中青年專家，全國抗擊新冠肺炎疫情先進個人，全國優秀共產黨員。現任國家傳染病醫學中心主任，狗万外围充值 附屬華山醫院感染科主任，狗万外围充值 臨床醫學院內科學係主任，上海市傳染病與生物安全應急響應重點實驗室主任，上海市新冠肺炎醫療救治專家組組長。

獲獎情況

榮獲全國創新爭先獎、上海市科技進步一等獎、上海市科普獎特等獎、中華醫學會醫學獎、上海市醫學科技獎等多項科技成果獎；並先後獲得全國科普工作先進工作者、國家健康科普專家庫入選者、上海市市長質量獎、2020年“最美教師、2021年“中國城市人物”、首屆“國之名醫·優秀風範”獎、科普傑出人物獎等獎。

研究成果及貢獻

長期專注於重大傳染性疾病流行消除診治創新技術的探索，並對新發突發傳染病的預警與大流行應對技術的建立作出貢獻。主要包括以下幾個方麵：

（一）消除結核病流行關鍵技術研究。長期致力於中國結核病流行消除與耐多藥結核病診治新技術方案探索。注冊中國最早的潛伏結核短程預防方案的RCT研究，優化和首創超短程潛伏結核預防治療，將療程從3個月縮短至1個月，在中國西部廣泛用於消除校園結核病的臨床實踐；提出國際上創新的短程治療策略，突破我國耐多藥結核病不足50%的低治愈率瓶頸；牽頭全國多中心臨床研究（中國PZA研究），研發出治愈率超80%的12個月短程治療方案，被《耐多藥結核病短程治療中國專家共識》、《中國耐多藥和利福平耐藥結核病治療專家共識(2019年版)》、《耐藥結核病診治規範(2019年版)》三個共識/規範共同推薦。耐多藥結核病治療方案連續被2016、2018、2022年WHO耐多藥結核病指南引用。

（二）致力於慢性乙肝的功能性治愈新策略研究。團隊長期致力於肝病的功能性治愈，明確了血清HBV-RNA水平與功能性治愈相關核心分子cccDNA的肝內轉錄活性的相關性。開發了針對慢性乙型肝炎的非整合型慢病毒載體治療性疫苗，大型臨床研究驗證了分階段免疫疊加治療獲得更高功能性治愈的治療理念。（三）新發傳染病的鑒定、監測與大流行準備技術研究。2013年起建立全國首個感染性疾病病原精準診斷中心平台，在全球首次經病原學和免疫學角度分別驗證豬偽狂犬病毒跨物種傳播，完成國際第一例通過宏基因組學技術快速鑒定非洲錐蟲病並成功救治危重患者的案例；在我國北方建立大型布魯菌病隊列，自然史研究成為國際醫學教育項目（ACCME）的經典案例；2020年新冠疫情爆發以來，在全球首次對兩針滅活疫苗+重組蛋白疫苗序貫免疫的保護性及其機製進行了研究，為國家第三針加強策略的部署提供依據；2023年全國首次報道奧密克戎長新冠隊列隨訪結果。團隊上述多個成果或被WHO指導文件引用並發表於高質量國際論文上。以第一作者/通訊作者在國內外期刊上發表論文300餘篇，包括SCI論文200餘篇。研究成果獲國家授權專利9項，主編及參編各類感染病學專著20餘部。

科研項目（近3年）

落地生科院包括國家重大專項、上海市重大專項、校企聯合實驗室等縱向和聯合實驗室橫向科研項目，總經費超3000萬元.

招生專業

微生物學、遺傳學

部分代表性論文（近3年）

  1. Zhang, Y., Q. Jiang, F. Sun, J. Wang, J. Wu, H. Yao, S. Li, N. Jiang, Q. Liu, Q. Liu, Y. Zhang, Y. Zhao, C. Chen, P. Cui, J. Jin and W. Zhang (2023). "Genomic tracking and precise control of Klebsiella pneumoniae transmission in a newly established hospital: a prospective molecular epidemiological study." Int J Antimicrob Agents 62(3): 106910.

  2. Zhang, H., M. Zhang, Q. Zhang, Y. Yu, F. Zhang, J. Wang, M. Zhou, T. Yu, C. Shen, S. Yu, Y. Huang, Y. Huang, J. Zhang, J. Jin, C. Qiu, L. Guojun and W. Zhang (2023). "Visualizing in situ viral replication across the natural history of chronic HBV infection." Hepatol Commun 7(4).

  3. Wu, Z., L. Lu, Y. Li, J. Chen, Z. Zhang, C. Ning, Z. Yuan, Q. Pan, X. Shen and W. Zhang (2023). "Effect of mobile health reminders on tuberculosis treatment outcomes in Shanghai, China: A prospective cohort study." Front Public Health 11: 923319.

  4. Wu, Q., H. Wang, J. Cai, J. Ai, Y. Li, H. Zhang, S. Wang, F. Sun, Y. Wu, J. Zhou, Y. Wang, H. Yu and W. Zhang (2023). "Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai." Emerg Microbes Infect 12(1): e2169197.

  5. Wang, H., Q. Xue, H. Zhang, G. Yuan, X. Wang, K. Sheng, C. Li, J. Cai, Y. Sun, J. Zhao, J. Lu, S. Fang, Y. Yang, Y. Zhang, Y. Huang, J. Wang, J. H. Xu, M. X. Jiang, X. Wang, L. Shen, Y. Liu, Q. Liu, Q. Zhang, S. Wang, P. Wang, C. Qiu, J. Ai and W. Zhang (2023). "Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination(1)." Emerg Microbes Infect 12(2): 2249121.

  6. Song, J., K. Zhu, X. Wang, Q. Yang, S. Yu, Y. Zhang, Z. Fu, H. Wang, Y. Zhao, K. Lin, G. Yuan, J. Guo, Y. Shi, C. Liu, J. Ai, H. Zhang and W. Zhang (2023). "Utility of clinical metagenomics in diagnosing malignancies in a cohort of patients with Epstein-Barr virus positivity." Front Cell Infect Microbiol 13: 1211732.

  7. Ruan, Q. L., Z. C. Wang, C. J. Wei, W. Wang, Q. L. Yang, J. Wu, Y. M. Wan, L. L. Ge, W. H. Zhang and Q. F. Li (2023). "Neutralizing antibodies against SARS-CoV-2 virus after vaccination in patients with neurofibromatosis type 1." Signal Transduct Target Ther 8(1): 233.

  8. Li, R., Y. Li, X. Chen, L. Jia, H. Yu, Y. Huang, Q. Wu, M. Xiao, S. Ge, Y. Zhang, Z. Feng, Q. Li, Y. Xu, W. Shi, F. Sun and W. Zhang (2023). "Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients." Microbiol Spectr 11(3): e0483622.

  9. Fu, Z., J. Ai, H. Zhang, P. Cui, T. Xu, Y. Zhang, Y. Zhang, H. Wu, A. Shen, K. Lin, M. Zhang, C. Qiu, N. Jiang, Y. Zhou and W. Zhang (2023). "Pathogen quantitative efficacy of different spike-in internal controls and clinical application in central nervous system infection with metagenomic sequencing." Microbiol Spectr: e0113923.

  10. Fu, L., X. Zhang, J. Xiong, F. Sun, T. Weng, Y. Li, P. Zhang, H. Li, Q. Yang, Y. Cai, H. Liang, Q. Chen, Z. Wang, L. Liu, X. Chen, W. Zhang and G. Deng (2023). "Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study." Int J Infect Dis 135: 101-108.

  11. Chen, X., R. Li, S. Ge, Y. Li, C. Cai, T. Weng, Y. Zhang, J. Jiang, Z. Feng, Y. Chen, Y. Zhang, J. Ma, D. H. Persing, J. Chen, Y. W. Tang, F. Sun and W. Zhang (2023). "Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients." J Clin Microbiol 61(6): e0183222.

  12. Cai, J., K. Lin, H. Zhang, Q. Xue, K. Zhu, G. Yuan, Y. Sun, F. Zhu, J. Ai, S. Wang and W. Zhang (2023). "A one-year follow-up study of systematic impact of long COVID symptoms among patients post SARS-CoV-2 omicron variants infection in Shanghai, China." Emerg Microbes Infect 12(2): 2220578.

  13. Zhang, Y., H. Zhang and W. Zhang (2022). "SARS-CoV-2 variants, immune escape, and countermeasures." Front Med 16(2): 196-207.

  14. Zhang, Y., N. Jiang, W. Qi, T. Li, Y. Zhang, H. Zhang, J. Wu, Z. Zhu, J. Ai, C. Qiu and W. Zhang (2022). "Intra-host SARS-CoV-2 single-nucleotide variants emerged during the early stage of COVID-19 pandemic forecast population fixing mutations." J Infect 84(5): 722-746.

  15. Zhang, Y., N. Jiang, W. Qi, T. Li, Y. Zhang, J. Wu, H. Zhang, M. Zhou, P. Cui, T. Yu, Z. Fu, Y. Zhou, K. Lin, H. Wang, T. Wei, Z. Zhu, J. Ai, C. Qiu and W. Zhang (2022). "SARS-CoV-2 intra-host single-nucleotide variants associated with disease severity." Virus Evol 8(2): veac106.

  16. Zhang, Y., J. Ai, J. Bao and W. Zhang (2022). "Lessons learned from the COVID-19 control strategy of the XXXII Tokyo Summer Olympics and the XXIV Beijing Winter Olympics." Emerg Microbes Infect 11(1): 1711-1716.

  17. Zhang, X., W. Zhang and S. Chen (2022). "Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic." Lancet 399(10340): 2011-2012.

  18. Zhang, H., W. Hua, S. Lin, Y. Zhang, X. Chen, S. Wang, J. Chen and W. Zhang (2022). "In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid." Infect Drug Resist 15: 4845-4852.

  19. Yang, Q. L., S. L. Yu, L. Y. Shao, Q. L. Ruan and W. H. Zhang (2022). "A 70-Year-Old Man With Fever and Fatigue." Clin Infect Dis 74(6): 1117-1119.

  20. Wang, X., J. Ai, X. Li, X. Zhao, J. Wu, H. Zhang, X. He, C. Zhao, R. Qiao, M. Li, Y. Cui, Z. Hu, C. Xu, W. Zhang and P. Wang (2022). "Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera." Cell Discov 8(1): 110.

  21. Wang, H., W. Zhang and Y. W. Tang (2022). "Clinical microbiology in detection and identification of emerging microbial pathogens: past, present and future." Emerg Microbes Infect 11(1): 2579-2589.

  22. Ruan, Q. L., Q. L. Yang, F. Sun, W. Liu, Y. J. Shen, J. Wu, N. Jiang, J. Y. Zhou, L. Y. Shao and W. H. Zhang (2022). "Recurrent pulmonary tuberculosis after treatment success: a population-based retrospective study in China." Clin Microbiol Infect 28(5): 684-689.

  23. Qi, X., J. Wang, Q. Zhang, J. Ai, C. Liu, Q. Li, Y. Gu, J. Lv, Y. Huang, Y. Liu, D. Xu, S. Chen, D. Liu, J. Li, H. Xiang, J. Liang, L. Bian, Z. Zhang, L. Liu, X. Zhang, W. Qin, X. Wang, Z. Hou, N. Zhang, A. Zhang, H. Zu, Y. Wang, Z. Yan, X. Du, A. Hou, J. Ji, J. Yang, J. Huang, Z. Zhao, S. Zou, H. Ji, G. Ge, Q. L. Zeng and W. Zhang (2022). "Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study." J Med Virol 94(11): 5553-5559.

  24. Ma, E., J. Ai, Y. Zhang, J. Zheng, X. Gao, J. Xu, H. Yin, Z. Fu, H. Xing, L. Li, L. Sun, H. Huang, Q. Zhang, L. Xu, Y. Jin, R. Chen, G. Lv, Z. Zhu, W. Zhang and Z. Wang (2022). "Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort." Emerg Microbes Infect 11(1): 2636-2644.

  25. Jia, L., S. Weng, J. Wu, X. Tian, Y. Zhang, X. Wang, J. Wang, D. Yan, W. Wang, F. Fang, Z. Zhu, C. Qiu, W. Zhang, Y. Xu and Y. Wan (2022). "Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity." Gut Microbes 14(1): 2117503.

  26. Chen, X., H. Wang, J. Ai, L. Shen, K. Lin, G. Yuan, X. Sheng, X. Jin, Z. Deng, J. Xu, G. Lu, S. Chen, J. Cai, Y. Zhang, H. Zhang, S. Wang, W. Zhang and C. Fan (2022). "Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort study." Emerg Microbes Infect 11(1): 2501-2509.

  27. Bao, J., R. Sun, J. Ai, L. Qian, F. Liu, H. Wang, L. Tan, X. Cai, Y. Shi, X. Liang, W. Ge, J. Wu, C. Chen, W. Zhang, J. Huang and T. Guo (2022). "Proteomic characterization of Omicron SARS-CoV-2 host response." Cell Discov 8(1): 46.

  28. Ai, J., Y. Zhang, H. Zhang, Q. Zhang, Z. Fu, K. Lin, J. Song, Y. Zhao, M. Fan, H. Wang, Y. Zhou, X. Chen, C. Qiu and W. Zhang (2022). "Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study." Emerg Microbes Infect 11(1): 639-647.

  29. Ai, J., H. Zhang, Y. Zhang, K. Lin, Y. Zhang, J. Wu, Y. Wan, Y. Huang, J. Song, Z. Fu, H. Wang, J. Guo, N. Jiang, M. Fan, Y. Zhou, Y. Zhao, Q. Zhang, Q. Liu, J. Lv, P. Li, C. Qiu and W. Zhang (2022). "Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost." Emerg Microbes Infect 11(1): 337-343.

  30. Ai, J., H. Zhang, Q. Zhang, Y. Zhang, K. Lin, Z. Fu, J. Song, Y. Zhao, M. Fan, H. Wang, C. Qiu, Y. Zhou and W. Zhang (2022). "Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern." Cell Res 32(1): 103-106.

  31. Ai, J., X. Wang, X. He, X. Zhao, Y. Zhang, Y. Jiang, M. Li, Y. Cui, Y. Chen, R. Qiao, L. Li, L. Yang, Y. Li, Z. Hu, W. Zhang and P. Wang (2022). "Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages." Cell Host Microbe 30(8): 1077-1083.e1074.

  32. Ai, J., J. Guo, H. Zhang, Y. Zhang, H. Yang, K. Lin, J. Song, Z. Fu, M. Fan, Q. Zhang, H. Wang, Y. Zhao, Z. He, A. Cui, Y. Zhou, J. Wu, M. Zhou, G. Yuan, B. Kang, N. Zhao, Y. Xu, M. Zhu, Y. Wang, Z. Zhang, N. Jiang, C. Qiu, C. Xu and W. Zhang (2022). "Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling." Cell Discov 8(1): 114.




Baidu
map